Genistein effect on cognition in prodromal Alzheimer's disease patients : the GENIAL clinical trial
Mostra el registre complet de l'element
Visualització
(1.154Mb)
|
|
|
|
|
|
Viña Ribes, José; Escudero, Joaquín; Baquero, Miquel; Cebrián, Mónica; Carbonell Asíns, Juan Antonio; Muñoz Cebriá, José Enrique; Satorres Pons, Encarnación; Meléndez Moral, Juan Carlos; Ferrer Rebolleda, José; Cozar Santiago, Maria del Puig; Santabárbara Gómez, José Manuel; Jové, Mariona; Pamplona, Reinald; Tarazona Santabalbina, Francisco José; Borrás Blasco, Consuelo
|
|
Aquest document és un/a article, creat/da en: 2022
|
|
|
|
Delaying the transition from minimal cognitive impairment to Alzheimer's dementia is a major concern in Alzheimer's disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet effective substances are recommended. There is a need to develop new drugs to delay Alzheimer's dementia. We have taken a nutritional supplement approach with genistein, a chemically defined polyphenol that acts by multimodal specific mechanisms. Our group previously showed that genistein supplementation is effective to treat the double transgenic (APP/PS1) AD animal model. |
|
Veure al catàleg Trobes
|
|
|
Aquest element apareix en la col·lecció o col·leccions següent(s)
Mostra el registre complet de l'element